139 related articles for article (PubMed ID: 8622078)
1. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.
Silvestrini R; Benini E; Veneroni S; Daidone MG; Tomasic G; Squicciarini P; Salvadori B
J Clin Oncol; 1996 May; 14(5):1604-10. PubMed ID: 8622078
[TBL] [Abstract][Full Text] [Related]
2. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.
Silvestrini R; Daidone MG; Mastore M; Di Fronzo G; Coradini D; Boracchi P; Squicciarini P; Salvadori B; Veronesi U
J Clin Oncol; 1993 Jun; 11(6):1150-5. PubMed ID: 8501501
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
Silvestrini R; Veneroni S; Benini E; Daidone MG; Luisi A; Leutner M; Maucione A; Kenda R; Zucali R; Veronesi U
J Natl Cancer Inst; 1997 May; 89(9):639-45. PubMed ID: 9150188
[TBL] [Abstract][Full Text] [Related]
5. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
7. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.
Silvestrini R; Daidone MG; Benini E; Faranda A; Tomasic G; Boracchi P; Salvadori B; Veronesi U
Clin Cancer Res; 1996 Dec; 2(12):2007-13. PubMed ID: 9816160
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.
Daidone MG; Luisi A; Martelli G; Benini E; Veneroni S; Tomasic G; De Palo G; Silvestrini R
Br J Cancer; 2000 Jan; 82(2):270-7. PubMed ID: 10646876
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers.
Silvestrini R; Daidone MG; Del Bino G; Mastore M; Luisi A; Di Fronzo G; Boracchi P
Ann Oncol; 1993 Mar; 4(3):213-9. PubMed ID: 8471553
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
12. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.
Kim K; Chie EK; Han W; Noh DY; Park IA; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
J Korean Med Sci; 2010 Feb; 25(2):235-9. PubMed ID: 20119576
[TBL] [Abstract][Full Text] [Related]
14. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.
Daidone MG; Veneroni S; Benini E; Tomasic G; Coradini D; Mastore M; Brambilla C; Ferrari L; Silvestrini R
Int J Cancer; 1999 Dec; 84(6):580-6. PubMed ID: 10567902
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.
Mauri FA; Maisonneuve P; Caffo O; Veronese S; Aldovini D; Ferrero S; Cozzaglio F; Dalla Palma P; Galligioni E; Barbareschi M
Int J Oncol; 1999 Dec; 15(6):1137-47. PubMed ID: 10568820
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
18. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
[TBL] [Abstract][Full Text] [Related]
20. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
